Viatris Inc. Common Stock VTRS
Analyst Ratings
- Consensus
- Moderate Buy — 3 Buy · 2 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $17.40 (+7.2% upside)
Key Stats
- Today's Range
- $15.88 – $16.27
- 50-Day Range
- $14.94 – $18.39
- 52-Week Range
- $8.63 – $18.39
- Volume
- 8.20 million shs
- Average Volume
- 10.44 million shs
- Market Cap
- $18.49 billion
- P/E Ratio
- —
- Dividend Yield
- 2.96%
Valuation
- P/E Ratio
- —
- Price / Book
- 1.30
- Price / Sales
- 1.25
Dividend
- Dividend Yield
- 2.96%
- Annual Dividend
- $0.48
- Payout Ratio
- —
- Ex-Dividend Date
- 2026-08-21
Short Interest
- Short Interest
- 4.03%
- Days to Cover
- 1.94
Financials (TTM)
- Revenue
- $14.74 billion
- Net Income
- $-410,700,000
- Net Margin
- -2.79%
- Return on Equity
- -2.88%
- Debt-to-Equity
- —
About Viatris Inc. Common Stock
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Related Stocks
Compare head-to-head: VTRS vs LLY·VTRS vs JNJ·VTRS vs ABBV·VTRS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.